Science and Research

MK-7339-008

A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Study details
Study-ID: NCT03976362, 2018-004721-88
Study-ID: NCT03976362, 2018-004721-88
DZL Disease Area: LC
DZL Disease Area: LC
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: CPC-M
DZL Participating Sites: CPC-M
Start Date: 28.06.2019
Completion Date: 12.03.2025
Status: Recruiting
Status: Recruiting
DZL recruiting center
Link to Study


chevron-down